These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 8563868

  • 1. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
    Munakata A, Yoshida Y, Muto T, Tsuchiya S, Fukushima T, Hiwatashi N, Kobayashi K, Kitano A, Shimoyama T, Inoue M.
    J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L, Cohen H, Dooley C, Rubin P, Orchard J.
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
    Marakhouski Y, Fixa B, Holomán J, Hulek P, Lukas M, Bátovský M, Rumyantsev VG, Grigoryeva G, Stolte M, Vieth M, Greinwald R, International Salofalk Study Group.
    Aliment Pharmacol Ther; 2005 Jan 15; 21(2):133-40. PubMed ID: 15679762
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
    Gibson PR, Fixa B, Pekárková B, Bátovský M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):1017-26. PubMed ID: 16573804
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun 01; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 9. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
    Raedler A, Behrens C, Bias P.
    Aliment Pharmacol Ther; 2004 Dec 01; 20(11-12):1353-63. PubMed ID: 15606398
    [Abstract] [Full Text] [Related]

  • 10. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R.
    Aliment Pharmacol Ther; 2006 Oct 01; 24(7):1087-97. PubMed ID: 16984503
    [Abstract] [Full Text] [Related]

  • 11. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB.
    Gastroenterology; 2009 Dec 01; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L, Gionchetti P, Blanco Gdel V, Orlando A, Annese V, Papi C, Sostegni R, D'Incà R, Petruzziello C, Casa A, Sica G, Calabrese E, Campieri M, Pallone F.
    Dig Liver Dis; 2007 Apr 01; 39(4):329-37. PubMed ID: 17347061
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
    Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, D'Arienzo A, Gaia E, Gullini S, Riegler G, Valentini M, Massa P, Del Piano M, Rossini F, Guidetti CS, Pera A, Greinwald R, Bianchi Porro G.
    Ital J Gastroenterol Hepatol; 1999 Nov 01; 31(8):677-84. PubMed ID: 10730559
    [Abstract] [Full Text] [Related]

  • 16. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
    Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M.
    Am J Gastroenterol; 1993 Aug 01; 88(8):1188-97. PubMed ID: 8338086
    [Abstract] [Full Text] [Related]

  • 17. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y.
    Clin Gastroenterol Hepatol; 2006 Dec 01; 4(12):1502-6. PubMed ID: 17101300
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
    Gong Y, Zha Q, Li L, Liu Y, Yang B, Liu L, Lu A, Lin Y, Jiang M.
    J Ethnopharmacol; 2012 Jun 01; 141(2):592-8. PubMed ID: 21911045
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].
    Ngô Y, Gélinet JM, Ivanovic A, Kac J, Schénowitz G, Vilotte J, Rambaud JC.
    Gastroenterol Clin Biol; 1992 Jun 01; 16(10):782-6. PubMed ID: 1478406
    [Abstract] [Full Text] [Related]

  • 20. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J, Yuan Y.
    Adv Ther; 2016 Mar 01; 33(3):400-9. PubMed ID: 26898569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.